Background {#Sec1}
==========

The broad implementation of early primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI) resulted in a significant improvement of clinical outcomes \[[@CR1], [@CR2]\]. Nevertheless, despite restoration of epicardial blood flow, adequate myocardial reperfusion cannot be achieved in a significant portion of patients-a phenomenon called 'no reflow' \[[@CR3]\]. Three distinct pathophysiological processes are critical in the development of 'no reflow' after PPCI for STEMI: distal embolization, ischemia-reperfusion injury, and individual susceptibility \[[@CR4]\].

Today cardiac magnetic resonance (CMR) imaging allows a comprehensive infarct characterization including the assessment of microvascular injury \[[@CR5]\]. Microvascular injury detected by the use of CMR imaging is generally called 'microvascular obstruction' (MVO) \[[@CR6]\]. In the so far largest prospective, multicenter study comprising more than 700 STEMI patients MVO provided independent and incremental prognostic value for the occurrence of major adverse cardiac events within 1 year after infarction \[[@CR7]\]. In the study by Cochet et al. MVO provided 84% sensitivity and 65% specificity for the prediction of major adverse cardiac events 1 year after reperfused AMI \[[@CR8]\]. Another study in STEMI patients proved MVO as an independent outcome predictor during a median long-term follow-up of 52 months \[[@CR9]\]. Importantly, presence of MVO provides incremental information over traditional outcome parameters like left ventricular (LV) ejection fraction and infarct size (IS) \[[@CR3], [@CR10]\]. Identification of MVO, therefore, could allow for ideal risk stratification in the early stage after acute STEMI, but is still hampered due to the limited availability of CMR in clinical routine \[[@CR11]\]. A biomarker model for prediction of MVO, which could easily be applied in a broad range of STEMI patients, might provide a practicable and cost effective alternative to CMR.

An association between serially measured cardiac troponin concentrations and CMR derived MVO has previously been reported for this patient cohort \[[@CR12], [@CR13]\]. However, these studies were hampered either due to a small sample size or the use of non-high-sensitivity troponin assays. Furthermore, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels obtained upon hospital admission for acute STEMI might be predictive for the presence of MVO \[[@CR14]\]. However, limited data are available regarding the relation of CMR derived MVO and other clinically available biomarkers apart from cardiac troponin and NT-proBNP \[[@CR12]--[@CR14]\]. Therefore, the aims of the present study were 1) to investigate the association of CMR-determined MVO with admission and peak concentrations of routinely measured laboratory markers (high-sensitivity cardiac troponin T (hs-cTnT), creatine kinase (CK), NT-proBNP, high-sensitivity C-reactive protein (hs-CRP), lactate dehydrogenase (LDH), aspartate transaminase (AST) and alanine transaminase (ALT)), 2) to assess the prognostic value of these biomarkers for the prediction of MVO and 3) to analyze the prognostic utility of a combined biomarker panel.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

One hundred and twenty-eight patients with first STEMI admitted to our coronary care unit were recruited to this single-center, prospective, observational study. Diagnosis of STEMI was based on the redefined ESC/ACC committee criteria \[[@CR15]\]. Inclusion criteria were reperfusion by PPCI and no contraindication for CMR examination. Exclusion criteria were age below 18 years, an estimated glomerular filtration rate \< 30 ml/min/1.73 m^2^ and Killip class ≥ 3 at admission. Data on patient characteristics were acquired with the help of a standardized questionnaire during hospitalization. Ischemia time was defined as the delay from symptom onset to the time-point of first balloon-inflation. The study complies with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the local ethics committee of Medical University of Innsbruck. Written informed consent was obtained from all patients before inclusion into the study.

Biochemical analysis {#Sec4}
--------------------

Blood samples were taken from a peripheral vein and immediately analyzed at our central laboratory. High-sensitivity cardiac troponin T (hs-cTnT) concentrations were measured using a fifth-generation high-sensitivity assay (Roche Diagnostics, Mannheim, Germany) \[[@CR16], [@CR17]\]. The analytical limit of detection was 5 ng/l and the 99^th^ percentile upper reference limit was 14 ng/l. The 10% coefficient of variation was 13 ng/l. Plasma NT-proBNP concentrations were measured as described in detail previously \[[@CR18], [@CR19]\]. The analytical limit of detection of NT-proBNP was 5 ng/l. Creatine kinase (CK), high-sensitivity C-reactive protein (hs-CRP), lactate dehydrogenase (LDH), aspartate transaminase (AST), and alanine transaminase (ALT) activities were measured by routine assays as described previously \[[@CR16], [@CR18]\].

hs-cTnT concentrations were determined on admission, subsequently three times during the first 24 h and then daily until day 4 or discharge. All other biomarkers were measured on admission and subsequently once daily up to day 4 after PPCI or discharge. Biomarker peak concentrations are regarded as the highest values in the concentration time-course.

Cardiac magnetic resonance imaging {#Sec5}
----------------------------------

All CMR scans were performed on a 1.5 Tesla Magnetom Avanto scanner (Siemens, Erlangen, Germany). The imaging protocol has been described in detail previously \[[@CR12]\]. In brief, true fast imaging steady-state precession (true-FISP) bright-blood sequences in the LV short axis were acquired to assess LV function and morphology. Image post-processing was performed using standard software (ARGUS, Siemens). IS and presence of MVO were derived from late gadolinium-enhanced images as previously described \[[@CR9]\]. A threshold of + 5 standard deviations was defined as 'hyperenhancement' \[[@CR20]\]. MVO was defined as a persisting area of hypoenhancement within hyperenhanced myocardium \[[@CR9]\].

Statistical analysis {#Sec6}
--------------------

Statistical analysis was performed using SPSS Statistics 22.0.0 (IBM, Armonk, NY, USA) and MedCalc 15.8 (Ostend, Belgium). To test for normal distribution (ND), Shapiro-Wilk test was used. Continuous data are expressed as mean ± standard deviation (SD) or as median with interquartile range (IQR) as appropriate. Categorical data are expressed as numbers with corresponding percentages. Pearson's (if ND) or Spearman's rank (if not ND) correlation coefficients were calculated. Differences in continuous variables between groups were calculated by Student's t-test, if ND. Otherwise, Mann-Whitney U test was used. To test for group-differences of categorical variables χ^2^-test was applied.

Receiver operator characteristics (ROC) analysis was used to determine the predictive value (area under the curve (AUC)) of biomarkers. Biomarkers which significantly differed between patients with and without MVO were included into ROC analyses. Binary logistic regression analysis was used as a statistical tool to combine biomarkers as previously described \[[@CR17]\]. The potentially incremental information of a combined biomarker model for the prediction of MVO was assessed by *c*-statistics. *C*-statistic results were compared using the method previously described by DeLong et al \[[@CR21]\]. Two-tailed p-values \< 0.05 were considered statistically significant.

Results {#Sec7}
=======

Patients and infarct-related characteristics {#Sec8}
--------------------------------------------

Mean age of the study cohort was 58 ± 10 years; 12 patients (9%) were female. Baseline characteristics of the study cohort are shown in Table [1](#Tab1){ref-type="table"}. The median delay to reperfusion was 220 min (IQR 155--417 min). Sixty-one patients (48%) presented with anterior infarct location. Seventy (56%), 34 (27%) and 21 (17%) patients showed 1-, 2- and 3-vessel disease according to coronary angiography, respectively. Culprit only PPCI was performed in all 128 patients. The culprit vessel was the right coronary artery in 55 (43%), the left anterior descending artery in 60 (47%), the left circumflex artery in 12 (9%) and the ramus intermedius in 1 (1%) cases.Table 1Patient characteristic of the overall cohort (*n =* 128) and after stratification for presence of MVOPatient characteristicsOverall cohortPresence of MVO(*n* = 128)no (*n* = 59, 46%)yes (*n* = 69, 54%)*p*Age, years58 ± 1057 ± 1058 ± 100.925Female, n (%)12 (9)8 (14)4 (6)0.223Body mass index, kg/m^2^26 (25--30)27 (26--29)26 (24--30)0.522Family history for AMI, n (%)34 (27)19 (32)15 (22)0.229Current smokers, n (%)63 (49)28 (48)35 (51)0.727RR~sys~, mmHg125 ± 24126 ± 23123 ± 240.491RR~dia~, mmHg77 ± 1578 ± 1476 ± 150.309Leucocyte count admission, G/l11.7 (8.8--14.5)11.5 (8.5--14.5)12.0 (9.0--14.6)0.649Leucocyte count max, G/l12.7 (10.8--15.8)11.9 (10.3--15.2)13.1 (11.7--16.4)0.061Total cholesterol, mg/dl192 ± 44185 ± 41198 ± 470.108Low-density lipoprotein, mg/dl128 ± 42123 ± 39132 ± 440.230High-density lipoprotein, mg/dl42 (36--49)40 (33--53)43 (38--49)0.320Triglycerides, mg/dl102 (78--151)108 (80--163)96 (77--142)0.276Plasma glucose admission, mg/dl135 (115--161)134 (116--163)137 (112--160)0.728HbA1c, %5.6 (5.4--6.0)5.6 (5.4--6.1)5.6 (5.3--5.9)0.792Creatinine admission, mg/dl0.93 (0.82--1.05)0.92 (0.76--1.07)0.93 (0.83--1.04)0.877Creatinine max, mg/dl1.04 (0.92--1.15)1.03 (0.91--1.13)1.06 (0.96--1.20)0.261hs-cTnT admission, ng/l226 (29--2168)201 (18--1388)523 (34--4001)**0.036**hs-cTnT max, ng/l5254 (2169--8735)2866 (1026--5524)6985 (4193--13639)**\<0.001**CK admission, U/l353 (174--1182)301 (148--862)435 (207--2433)**0.048**CK max, U/l2111 (1168--3674)1228 (625--2323)2776 (1749--4686)**\<0.001**NT-proBNP admission, ng/l139 (66--511)128 (66--360)159 (71--687)0.487NT-proBNP max, ng/l717 (184--1700)360 (131--924)1084 (312--2649)**0.003**hs-CRP admission, mg/dl0.23 (0.11--0.61)0.34 (0.15--0.66)0.19 (0.09--0.56)0.119hs-CRP max, mg/dl2.20 (0.96--4.56)1.53 (0.64 3.02)2.84 (1.68--7.44)**\<0.001**LDH admission, U/l238 (196--364)222 (182--301)257 (207--493)**0.009**LDH max, U/l593 (354--882)358 (271--624)742 (534--1182)**\<0.001**AST admission, U/l82 (34--210)57 (31--113)126 (40--306)**0.008**AST max, U/l239 (128--423)151 (75--256)340 (213--547)**\<0.001**ALT admission, U/l37 (27--58)31 (25--46)45 (32--75)**0.003**ALT max, U/l60 (42--87)47 (32--69)71 (52--111)**\<0.001**γGT admission, U/l37 (25--52)36 (26--50)39 (23--59)0.857γGT max, U/l40 (26--63)37 (26--51)41 (26--71)0.482AP admission, U/l64 (53--79)64 (52--80)63 (54--76)0.918AP max, U/l64 (53--81)64 (52--83)64 (54--81)0.951Total bilirubin admission, mg/dl0.49 (0.38--0.69)0.44 (0.37--0.65)0.52 (0.40--0.73)0.160Total bilirubin max, mg/dl0.62 (0.43--0.84)0.60 (0.42--0.84)0.62 (0.45--0.85)0.668*MVO* Microvascular Obstruction, *AMI* Acute Myocardial Infarction, *RR* ~*sys*~ Systolic Blood Pressure, *RR* ~*dia*~ Diastolic Blood Pressure, *hs-cTnT* High-Sensitivity Cardiac Troponin T, *CK* Creatine Kinase, *NT-proBNP* N-terminal pro-B-type natriuretic peptide, *hs-CRP* High-Sensitivity C-Reactive Protein, *LDH* Lactate Dehydrogenase, *AST* Aspartate Transaminase, *ALT* Alanine Transaminase, *γGT* Gamma-Glutamyltransferase, *AP* Alkaline PhosphataseBold data indicate statistical significance

CMR scans were performed at a median of 3 days after infarction (IQR 2--4 days). Median IS was 13% (IQR 8--25%). Mean LVEF was 54 ± 10%. MVO was present in 69 patients (54%).

Predictors of MVO {#Sec9}
-----------------

The delay from symptom onset to mechanical reperfusion did not significantly differ between patients with and without MVO (median = 213 min, IQR 149--399 min vs median = 240 min, IQR 154--424 min; *p* = 0.469). Patients showing MVO were more likely to have anterior infarcts compared to patients without MVO (*n* = 39, 57% vs *n =* 22, 37%; *p* = 0.030). No association was detected between the presence of MVO and the number of diseased epicardial coronary arteries (*p* = 0.480).

Patients with presence of MVO showed significantly higher IS (media*n =* 21%, IQR 14--30% vs median = 9%, IQR 3--13%; *p* \< 0.001), EDV (153 ± 30 ml vs 140 ± 26 ml; *p* = 0.010), ESV (median = 73 ml, IQR 60--90 ml vs median = 56 ml, IQR 44--72 ml; *p* \< 0.001) and lower LVEF (50 ± 9% vs 59 ± 10%; *p* \< 0.001). The occurrence of MVO did not significantly differ between patients with one- and multivessel disease (*p* = 0.286).

Differences in biomarker levels between patients with and without MVO are shown in Table [1](#Tab1){ref-type="table"}.

hs-cTnT concentrations at admission provided an AUC value of 0.61 (95% CI 0.52--0.69) for the prediction of MVO (Fig. [1a](#Fig1){ref-type="fig"}). AUCs did not significantly differ between admission hs-cTnT, CK, NT-proBNP, hs-CRP, LDH, AST and ALT (range 0.54, 95% CI 0.45--0.62 to 0.66, 95% CI 0.57--0.74; all *p* \> 0.080).Fig. 1Receiver operator characteristics (ROC) analyses comparing the predictive utility of admission and peak concentrations of **a**) hs-cTnT (AUC = 0.61, 95% CI 0.52--0.69 vs AUC = 0.77, 95% CI 0.68--0.85; *p* \< 0.001), **b**) CK (AUC = 0.60, 95% CI 0.51--0.69 vs AUC = 0.77, 95% CI 0.69--0.84; *p* = 0.001), **c**) NT-proBNP (AUC = 0.54, 95% CI 0.45--0.62 vs AUC = 0.64, 95% CI 0.55--0.73; *p* = 0.011) **d**) hs-CRP (AUC = 0.58, 95% CI 0.49--0.67 vs AUC = 0.68, 95% CI 0.60--0.76; *p* = NA), **e**) LDH (AUC = 0.64, 95% CI 0.54--0.72 vs AUC = 0.79, 95% CI 0.71--0.86; *p* = 0.003), **f**) AST (AUC = 0.64, 95% CI 0.55--0.72 vs AUC = 0.78, 95% CI 0.70--0.85, *p* = 0.005) and **g**) ALT (AUC = 0.66, 95% CI 0.57--0.74 vs AUC = 0.73, 95% CI 0.64--0.80; *p* = 0.049). hs-cTnT = High-Sensitivity Cardiac Troponin T; CK = Creatine Kinase; NT-proBNP = N-terminal pro-B-type natriuretic peptide; hs-CRP = High-Sensitivity C-Reactive Protein; LDH = Lactate Dehydrogenase; AST = Aspartate Transaminase; ALT = Alanine Transaminase

Biomarker peak concentrations provided significantly higher prognostic value for the prediction of MVO than corresponding admission values (all *p* \< 0.050) (Fig. [1](#Fig1){ref-type="fig"}).

Peak hs-cTnT concentrations provided an AUC of 0.77 (95% CI 0.68--0.85) for the prediction of MVO. Peak CK (AUC = 0.77, 95% CI 0.69--0.84; *p* = 0.882), hs-CRP (AUC = 0.68, 95% CI 0.60--0.76; *p* = 0.108), LDH (AUC = 0.79, 95% CI 0.71--0.86; *p* = 0.336), AST (AUC = 0.78, 95% CI 0.70--0.85; *p* = 0.517) and ALT (AUC = 0.73, 95% CI 0.64--0.80; *p* = 0.312) showed similar AUCs for the prediction of MVO compared to hs-cTnT. NT-proBNP peak concentrations (AUC = 0.64, 95% CI 0.55--0.73) exhibited significantly lower predictive utility compared to peak hs-cTnT (*p* = 0.027), CK (*p* = 0.031), LDH (*p* = 0.007) and AST (*p* = 0.016) concentrations. Optimal biomarker cut-off values with corresponding sensitivity, specificity as well as positive and negative predictive values for the prediction of MVO are summarized in Table [2](#Tab2){ref-type="table"}.Table 2Biomarker cut-off values providing optimal sensitivity, specificity as well as positive and negative predictive valuesoptimal cut-offsensitivityspecificityPPVNPVhs-cTnT max, ng/l438775687370CK max, U/l195973697369NT-proBNP max, ng/l55170636964hs-CRP max, mg/dl2,1167636862LDH max, U/l49682707677AST max, U/l22475717571ALT max, U/l5773647067*hs-cTnT* High-Sensitivity Cardiac Troponin T, *CK* Creatine Kinase, *NT-proBNP* N-terminal pro-B-type natriuretic peptide, *hs-CRP* High-Sensitivity C-Reactive Protein, *LDH* Lactate Dehydrogenase, *AST* Aspartate Transaminase, *ALT* Alanine Transaminase

Including peak CK, NT-proBNP, hs-CRP, LDH, AST and ALT concentrations additionally to peak hs-cTnT levels did not result in a significantly higher accuracy for the prediction of MVO (AUC = 0.79, 95% CI 0.71--0.87 vs AUC = 0.77, 95% CI 0.68--0.85; *p* = 0.349) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Receiver operator characteristics (ROC) curves of peak hs-cTnT concentrations and a combined biomarker model. Combination of biomarkers did not result in significantly higher prognostic value for the prediction of MVO compared to hs-cTnT alone (AUC = 0.79, 95% CI 0.71--0.87 vs AUC = 0.77, 95% CI 0.68--0.85; *p* = 0.349). hs-cTnT = High-Sensitivity Cardiac Troponin T; CK = Creatine Kinase; NT-proBNP = N-terminal pro-B-type natriuretic peptide; hs-CRP = High-Sensitivity C-Reactive Protein; LDH = Lactate Dehydrogenase; AST = Aspartate Transaminase; ALT = Alanine Transaminase

Discussion {#Sec10}
==========

This study for the first time comprehensively assessed the incremental value of routine biomarkers for the prediction of MVO after reperfused STEMI. The major findings were that 1) presence of MVO was associated with higher plasma concentrations of hs-cTnT, CK, hs-CRP, LDH, AST and ALT; 2) biomarker peak concentrations provided significantly higher prognostic value compared to admission values; 3) peak concentrations of hs-cTnT, CK, hs-CRP, LDH, AST and ALT showed similar prognostic value for the prediction of MVO, whereas the prognostic utility of peak NT-proBNP was lower; and 4) a model including peak CK, NT-proBNP, hs-CRP, LDH, AST and ALT concentrations additionally to hs-cTnT did not result in a significantly higher accuracy for the prediction of MVO.

Inadequate myocardial reperfusion despite restoration of epicardial coronary artery patency is attributed to microvascular injury \[[@CR22]\]. As previously shown, application of modern antiplatelet therapy partly improves microvascular perfusion \[[@CR23]\]. Interestingly, removal of thrombotic material by thrombus aspiration is ineffective in improvement of myocardial reperfusion \[[@CR24]\]. In the present study microvascular injury, defined as the presence or absence of CMR derived MVO, was detected in 54% of patients. This is in line with data from literature, reporting an up to 60% rate of MVO in patients receiving primary PCI for acute STEMI \[[@CR3]\]. In the present study culprit only revascularization was performed during PPCI. Thus, the impact of culprit only versus complete PPCI on MVO could not be analysed in the present study. This important topic was recently investigated in a well-conducted meta-analysis \[[@CR25]\].

Besides its ability for accurate quantification of ventricular function, morphology and infarct size, CMR imaging has emerged as the most reliable imaging modality to detect microvascular injury and is therefore more and more used to define surrogate endpoints in clinical trials \[[@CR5], [@CR26], [@CR27]\]. There is strong evidence that presence of MVO derived from late gadolinium-enhanced images is the best CMR prognosticator regarding clinical outcome after acute reperfused STEMI \[[@CR3], [@CR7]\]. Nevertheless, its determination is hampered since CMR is still a rarely available, expensive tool with restricted application in clinical routine. Thus, implementation of a biomarker model, which reliably allows for the prediction of MVO, is of clinical and prognostic importance \[[@CR28]\].

In the present study, time to reperfusion did not differ between patients with and without MVO. Presumably, this is due to the fact that microvascular dysfunction might persist even after restoration of epicardial blood flow \[[@CR3], [@CR29]\].

In line with data from literature, we detected a relation between the presence of MVO and infarct size, LV systolic function and morphology \[[@CR30]--[@CR32]\].

An association between cardiac troponin concentrations and CMR derived MVO has already been reported by several studies \[[@CR13], [@CR33], [@CR34]\]. Notably, the significance of these studies is limited due to an either small sample size and poorly defined patient selection (STEMI and non-STEMI patients included) or inconsistent reperfusion strategies. These limitations were obviated in the study by Mayr et al, since the relation between MVO and cardiac troponin levels was confirmed in a large, well-defined cohort of STEMI patients \[[@CR12]\]. However, in this study a non-high-sensitivity cardiac troponin T assay was used. These assays provide lower prognostic value and are associated with a longer troponin-blind period compared to new-generation high-sensitivity assays \[[@CR35]\]. This fact might particularly impact on the prognostic utility of admission troponin levels.

The present study extends previous findings, as we investigated the predictive value of a broad range of routinely used laboratory markers including high-sensitivity cardiac troponin T. All patients were exclusively reperfused by primary PCI, which is of importance since reperfusion strategy might influence the occurrence of MVO. Furthermore, high patient selection, as performed in the present study, reduced the presence of co-morbidities and consequently allowed to investigate predictors of MVO independently of concomitant cardiovascular disease.

Interestingly, peak concentrations of hs-cTnT, CK, hs-CRP, LDH, AST and ALT provided similar prognostic values for the prediction of MVO. This might be of practical significance, in particular if high-sensitivity troponin assays are not available in clinical routine. On the other hand, combining hs-cTnT with other biomarkers did not further improve the prognostic value compared to a model solely including hs-cTnT.

To a certain extent, biomarkers investigated in the present study have already been linked to clinical outcome following AMI \[[@CR36]\]. Moreover, in AMI patients prognostic utility was even proved for novel, upcoming biomarkers like galectin-3 \[[@CR37]\]. Although an association between biomarkers and hard clinical endpoints was shown in previous studies, the present study adds some causal relation, particularly since MVO is among the strongest predictors of poor outcome after STEMI \[[@CR7]\].

Besides its prognostic value, the therapeutic relevance of MVO has been demonstrated in several studies. For instance, modern antiplatelet therapy might improve microvascular perfusion \[[@CR23]\]. Moreover, in patients with successfully reperfused AMI treatment with statins before infarction was associated with a reduction of microvascular injury \[[@CR38]\].

Limitations {#Sec11}
-----------

This is the largest CMR study investigating a comprehensive biomarker model for the prediction of MVO. Nevertheless, further confirmation in larger cohorts is necessary. Remarkably, sensitivity and specificity is less than 80% for almost all biomarkers observed in the present study. These biomarkers reflect myocardial injury, haemodynamic alterations and inflammation. However, the occurrence of MVO is a rather complex pathophysiological process and, to a certain extent, a still unresolved topic \[[@CR39]\]. Possibly, the analysis of other, upcoming chemical markers might further improve the predictive value for the occurrence of MVO and should be investigated in future studies \[[@CR36], [@CR40]\].

In the present study the proportion of female patients was very low. Out of twelve female patients totally included only four patients developed MVO. Therefore, gender-specific, valid statistical analysis could not be performed. However, the impact of gender on outcome in STEMI patients has already been shown \[[@CR41]\]. Thus, further studies are needed investigating gender-specific differences in the prediction of MVO.

The present study focused on the prediction of MVO derived from CMR. Therefore, angiographic assessment of myocardial blush grade and the relatively novel wire-based technique to measure the index of microcirculatory resistance were not performed in this study \[[@CR42]\].

Conclusions {#Sec12}
===========

hs-cTnT, CK, hs-CRP, LDH, AST and ALT peak concentrations provided similar prognostic value for the prediction of CMR derived MVO in acute STEMI patients reperfused by PPCI. In comparison, the prognostic utility of peak NT-proBNP was lower. Combination of these biomarkers did not add any additional prognostic value. Since presence of MVO is among the strongest surrogate end-points for adverse clinical outcome after acute STEMI, our findings could contribute to optimize risk stratification early after the acute event.
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